NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE: ANVS) today announces its placement in an editorial published by NetworkNewsWire ('NNW'), one of 60+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.To view the full publication, “Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition,” please visit: https://nnw.fm/ZIUidAlzheimer’s disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S.

2024年10月2日，纽约（环球通讯社）--通过InvestorWire，安诺维斯生物公司（纽约证券交易所：ANVS）今天宣布其在NetworkNewsWire（“NNW”）发表的社论中的位置，NetworkNewsWire是动态品牌中60多个品牌之一Portfolio@IBN（InvestorBrandNetwork）是一个专门的通信平台，专注于为私营和上市公司以及投资界发布财务新闻和内容。要查看完整出版物“改变阿尔茨海默氏病治疗：创新组合以提高认知”，请访问：https://nnw.fm/ZIUidAlzheimer随着Leqembi和Kisulla等近期药物在美国上市，阿尔茨海默病（AD）已成为制药行业的焦点。

Food and Drug Administration (FDA) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer's.However, there is no molecule or a combination of molecules that enhance cognitive functions.

。然而，虽然这些治疗可能会减缓AD患者的认知能力下降，但实际上并没有改善认知能力，这是数百万患有进行性疾病的人的关键目标。此外，最初开发用于治疗2型糖尿病的GLP-1（胰高血糖素样肽-1）药物在治疗肥胖方面具有显着的有效性，也显示出治疗阿尔茨海默病的潜力。然而，没有分子或分子组合可以增强认知功能。

Thanks to innovative approaches by companies such as Annovis Bio Inc., there is reason to be optimistic about potential future breakthroughs in the AD space. Annovis has completed early research with compelling results utilizing its lead drug, buntanetap, in combination with popular drugs approved for other indications.About Annovis Bio Inc.Annovis Bio, headquartered in Malvern, Pennsylvania, is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”).

。Annovis利用其先导药物buntanetap以及批准用于其他适应症的流行药物完成了早期研究，取得了令人信服的结果。关于Annovis Bio Inc.总部位于宾夕法尼亚州马尔文的Annovis Bio致力于解决阿尔茨海默氏病（“AD”）和帕金森氏病（“PD”）等疾病中的神经退行性疾病。

The compan.

公司。